Cargando…

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study

OBJECTIVE: To investigate the associations of plasma levels of soluble receptor for advanced glycation end products (sRAGE) with incident cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes and the extent to which any such associations could be explained by endothelial and renal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nin, Johanna W.M., Jorsal, Anders, Ferreira, Isabel, Schalkwijk, Casper G., Prins, Martin H., Parving, Hans-Henrik, Tarnow, Lise, Rossing, Peter, Stehouwer, Coen D.A.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Complications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911054/ https://www.ncbi.nlm.nih.gov/pubmed/20522598 http://dx.doi.org/10.2337/db09-1509

Ejemplares similares

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
por: Nin, Johanna W., et al.
Publicado: (2011)

Comment on: Selvin et al. sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. Diabetes 2013;62:2116–2121
por: Schalkwijk, Casper G., et al.
Publicado: (2013)

Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
por: Nin, J. W. M., et al.
Publicado: (2012)

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
por: Soro-Paavonen, Aino, et al.
Publicado: (2008)

Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD
por: Pratte, Katherine A., et al.
Publicado: (2021)

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies
por: Peeters, Stijn A., et al.
Publicado: (2017)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD
por: Gopal, Poornima, et al.
Publicado: (2014)

Serum Heat Shock Protein 27 and Diabetes Complications in the EURODIAB Prospective Complications Study : A Novel Circulating Marker for Diabetic Neuropathy
por: Gruden, Gabriella, et al.
Publicado: (2008)

Advanced glycation end products and their soluble receptor (sRAGE) in patients with Hashimoto’s thyroiditis on levothyroxine substitution
por: Csiha, Sára, et al.
Publicado: (2023)

Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis
por: Wu, Rui, et al.
Publicado: (2020)

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
por: Peeters, S. A., et al.
Publicado: (2017)

Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension
por: Diekmann, Franziska, et al.
Publicado: (2021)

Diagnostic Utility and Tendency of Bronchial and Serum Soluble Receptor for Advanced Glycation EndProducts (sRAGE) in Lung Cancer
por: Kim, Taehee, et al.
Publicado: (2023)

RAGE and Modulation of Ischemic Injury in the Diabetic Myocardium
por: Bucciarelli, Loredana G., et al.
Publicado: (2008)

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort
por: Ferreira, Isabel, et al.
Publicado: (2017)

Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients
por: Jung, Eul Sik, et al.
Publicado: (2017)

The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes
por: Erusalimsky, Jorge D.
Publicado: (2021)

Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE)
por: Nowak, Agnieszka, et al.
Publicado: (2021)

SUN-LB131 Association of Receptor for Advanced Glycation End Product (RAGE) Gene Polymorphisms & Serum Levels of Soluble RAGE (sRAGE) With Metabolic Syndrome (MS) in Mexican Population
por: Gonzalez-Guerrero, Diana Elizabeth, et al.
Publicado: (2020)

The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease
por: Chen, Der-Yuan, et al.
Publicado: (2015)

Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients
por: Dozio, Elena, et al.
Publicado: (2018)

Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study
por: Saputra, Gusti Noor Ramadany, et al.
Publicado: (2022)

In Patients with Chronic Kidney Disease Advanced Glycation End-Products Receptors Isoforms (sRAGE and esRAGE) Are Associated with Malnutrition
por: Caldiroli, Lara, et al.
Publicado: (2022)

Polymorphisms −374 T/A and −429 T/C of the Receptor for Advanced Glycation End-Products (RAGE) and Serum Levels of RAGE (sRAGE) Are Not Associated with Metabolic Syndrome
por: González-Guerrero, Diana Elizabeth, et al.
Publicado: (2023)

RAGE Deficiency Improves Postinjury Sciatic Nerve Regeneration in Type 1 Diabetic Mice
por: Juranek, Judyta K., et al.
Publicado: (2013)

Affimers as an Alternative to Antibodies in an Affinity LC–MS Assay for Quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in Human Serum
por: Klont, Frank, et al.
Publicado: (2018)

The Assessment of Serum Concentrations of AGEs and Their Soluble Receptor (sRAGE) in Multiple Sclerosis Patients
por: Damasiewicz-Bodzek, Aleksandra, et al.
Publicado: (2021)

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial
por: Colhoun, Helen M., et al.
Publicado: (2011)

Oleic Acid Status Positively Correlates with the Soluble Receptor for Advanced Glycation End-Products (sRAGE) in Healthy Adults Who Are Homozygous for G Allele of RAGE G82S Polymorphism
por: Deo, Permal, et al.
Publicado: (2023)

Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice
por: Watson, Anna M.D., et al.
Publicado: (2012)

Soluble Receptor for Advanced Glycation End-Product (sRAGE)/Pentosidine Ratio: A Potential Risk Factor Determinant for Type 2 Diabetic Retinopathy
por: Ng, Zhi Xiang, et al.
Publicado: (2013)

Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss
por: Popp, Collin J, et al.
Publicado: (2022)

Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients
por: Assiri, Adel M. A., et al.
Publicado: (2018)

Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes
por: Selvin, Elizabeth, et al.
Publicado: (2011)

Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
por: Eleazu, Chinedum, et al.
Publicado: (2019)

sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death
por: Selvin, Elizabeth, et al.
Publicado: (2013)

Acute and Chronic Effects of Cigarette Smoking on sRAGE
por: Biswas, Subrata K.
Publicado: (2019)

The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes
por: Klein, Ronald, et al.
Publicado: (2017)

Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality
por: Lim, Adeline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3m7l8ib07dv983bm77bqb4sval